Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-Endoribonuclease.

Colombano G, Caldwell JJ, Matthews TP, Bhatia C, Joshi A, McHardy T, Mok NY, Newbatt Y, Pickard L, Strover J, Hedayat S, Walton MI, Myers SM, Jones AM, Saville H, McAndrew C, Burke R, Eccles SA, Davies FE, Bayliss R, Collins I.

J Med Chem. 2019 Mar 14;62(5):2447-2465. doi: 10.1021/acs.jmedchem.8b01721. Epub 2019 Mar 5.

2.

Correction: In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors.

Sharp SY, Boxall K, Rowlands M, Prodromou C, Roe SM, Maloney A, Powers M, Clarke PA, Box G, Sanderson S, Patterson L, Matthews TP, Cheung KJ, Ball K, Hayes A, Raynaud F, Marais R, Pearl L, Eccles S, Aherne W, McDonald E, Workman P.

Cancer Res. 2019 Jan 1;79(1):287. doi: 10.1158/0008-5472.CAN-18-3578. No abstract available.

PMID:
30602624
3.

Joint reconstruction of the initial pressure and speed of sound distributions from combined photoacoustic and ultrasound tomography measurements.

Matthews TP, Anastasio MA.

Inverse Probl. 2017 Dec;33(12). pii: 124002. doi: 10.1088/1361-6420/aa9384. Epub 2017 Nov 8.

4.

A forward-adjoint operator pair based on the elastic wave equation for use in transcranial photoacoustic computed tomography.

Mitsuhashi K, Poudel J, Matthews TP, Garcia-Uribe A, Wang LV, Anastasio MA.

SIAM J Imaging Sci. 2017;10(4):2022-2048. doi: 10.1137/16M1107619. Epub 2017 Nov 16.

5.

Parameterized joint reconstruction of the initial pressure and sound speed distributions for photoacoustic computed tomography.

Matthews TP, Poudel J, Li L, Wang LV, Anastasio MA.

SIAM J Imaging Sci. 2018;11(2):1560-1588. doi: 10.1137/17M1153649. Epub 2018 Jun 5.

6.

Regularized Dual Averaging Image Reconstruction for Full-Wave Ultrasound Computed Tomography.

Matthews TP, Wang K, Li C, Duric N, Anastasio MA.

IEEE Trans Ultrason Ferroelectr Freq Control. 2017 May;64(5):811-825. doi: 10.1109/TUFFC.2017.2682061. Epub 2017 Mar 14.

7.

Mitigation of artifacts due to isolated acoustic heterogeneities in photoacoustic computed tomography using a variable data truncation-based reconstruction method.

Poudel J, Matthews TP, Li L, Anastasio MA, Wang LV.

J Biomed Opt. 2017 Apr 1;22(4):41018. doi: 10.1117/1.JBO.22.4.041018.

8.

Generation of anatomically realistic numerical phantoms for photoacoustic and ultrasonic breast imaging.

Lou Y, Zhou W, Matthews TP, Appleton CM, Anastasio MA.

J Biomed Opt. 2017 Apr 1;22(4):41015. doi: 10.1117/1.JBO.22.4.041015.

9.

A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoforms.

Jones AM, Westwood IM, Osborne JD, Matthews TP, Cheeseman MD, Rowlands MG, Jeganathan F, Burke R, Lee D, Kadi N, Liu M, Richards M, McAndrew C, Yahya N, Dobson SE, Jones K, Workman P, Collins I, van Montfort RL.

Sci Rep. 2016 Oct 6;6:34701. doi: 10.1038/srep34701.

10.

Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).

Osborne JD, Matthews TP, McHardy T, Proisy N, Cheung KM, Lainchbury M, Brown N, Walton MI, Eve PD, Boxall KJ, Hayes A, Henley AT, Valenti MR, De Haven Brandon AK, Box G, Jamin Y, Robinson SP, Westwood IM, van Montfort RL, Leonard PM, Lamers MB, Reader JC, Aherne GW, Raynaud FI, Eccles SA, Garrett MD, Collins I.

J Med Chem. 2016 Jun 9;59(11):5221-37. doi: 10.1021/acs.jmedchem.5b01938. Epub 2016 May 23.

11.

A Constrained Variable Projection Reconstruction Method for Photoacoustic Computed Tomography Without Accurate Knowledge of Transducer Responses.

Sheng Q, Wang K, Matthews TP, Xia J, Zhu L, Wang LV, Anastasio MA.

IEEE Trans Med Imaging. 2015 Dec;34(12):2443-58. doi: 10.1109/TMI.2015.2437356.

12.

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.

Walton MI, Eve PD, Hayes A, Henley AT, Valenti MR, De Haven Brandon AK, Box G, Boxall KJ, Tall M, Swales K, Matthews TP, McHardy T, Lainchbury M, Osborne J, Hunter JE, Perkins ND, Aherne GW, Reader JC, Raynaud FI, Eccles SA, Collins I, Garrett MD.

Oncotarget. 2016 Jan 19;7(3):2329-42. doi: 10.18632/oncotarget.4919.

13.

Label-free photoacoustic microscopy of peripheral nerves.

Matthews TP, Zhang C, Yao DK, Maslov K, Wang LV.

J Biomed Opt. 2014 Jan;19(1):16004. doi: 10.1117/1.JBO.19.1.016004.

14.

Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies.

Matthews TP, Jones AM, Collins I.

Expert Opin Drug Discov. 2013 Jun;8(6):621-40. doi: 10.1517/17460441.2013.788496. Epub 2013 Apr 18. Review.

15.

Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.

Lainchbury M, Matthews TP, McHardy T, Boxall KJ, Walton MI, Eve PD, Hayes A, Valenti MR, de Haven Brandon AK, Box G, Aherne GW, Reader JC, Raynaud FI, Eccles SA, Garrett MD, Collins I.

J Med Chem. 2012 Nov 26;55(22):10229-40. doi: 10.1021/jm3012933. Epub 2012 Oct 19.

16.

CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.

Walton MI, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G, Hallsworth A, Smith EL, Boxall KJ, Lainchbury M, Matthews TP, Jamin Y, Robinson SP, Aherne GW, Reader JC, Chesler L, Raynaud FI, Eccles SA, Collins I, Garrett MD.

Clin Cancer Res. 2012 Oct 15;18(20):5650-61. doi: 10.1158/1078-0432.CCR-12-1322. Epub 2012 Aug 28.

17.

Electron paramagnetic resonance dosimetry for a large-scale radiation incident.

Swartz HM, Flood AB, Williams BB, Dong R, Swarts SG, He X, Grinberg O, Sidabras J, Demidenko E, Gui J, Gladstone DJ, Jarvis LA, Kmiec MM, Kobayashi K, Lesniewski PN, Marsh SD, Matthews TP, Nicolalde RJ, Pennington PM, Raynolds T, Salikhov I, Wilcox DE, Zaki BI.

Health Phys. 2012 Sep;103(3):255-67. doi: 10.1097/HP.0b013e3182588d92.

18.

Advances towards using finger/toenail dosimetry to triage a large population after potential exposure to ionizing radiation.

He X, Gui J, Matthews TP, Williams BB, Swarts SG, Grinberg O, Sidabras J, Wilcox DE, Swartz HM.

Radiat Meas. 2011 Sep;46(9):882-887.

19.

Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.

Reader JC, Matthews TP, Klair S, Cheung KM, Scanlon J, Proisy N, Addison G, Ellard J, Piton N, Taylor S, Cherry M, Fisher M, Boxall K, Burns S, Walton MI, Westwood IM, Hayes A, Eve P, Valenti M, de Haven Brandon A, Box G, van Montfort RL, Williams DH, Aherne GW, Raynaud FI, Eccles SA, Garrett MD, Collins I.

J Med Chem. 2011 Dec 22;54(24):8328-42. doi: 10.1021/jm2007326. Epub 2011 Nov 23.

20.

A Deployable In Vivo EPR Tooth Dosimeter for Triage After a Radiation Event Involving Large Populations.

Williams BB, Dong R, Flood AB, Grinberg O, Kmiec M, Lesniewski PN, Matthews TP, Nicolalde RJ, Raynolds T, Salikhov IK, Swartz HM.

Radiat Meas. 2011 Sep 1;46(9):772-777.

21.

Physically-based biodosimetry using in vivo EPR of teeth in patients undergoing total body irradiation.

Williams BB, Dong R, Nicolalde RJ, Matthews TP, Gladstone DJ, Demidenko E, Zaki BI, Salikhov IK, Lesniewski PN, Swartz HM.

Int J Radiat Biol. 2011 Aug;87(8):766-75. doi: 10.3109/09553002.2011.583316. Epub 2011 Jun 23.

22.

Design and evaluation of 3-aminopyrazolopyridinone kinase inhibitors inspired by the natural product indirubin.

Smyth LA, Matthews TP, Collins I.

Bioorg Med Chem. 2011 Jun 1;19(11):3569-78. doi: 10.1016/j.bmc.2011.03.069. Epub 2011 Apr 13.

PMID:
21536449
23.

Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases.

Matthews TP, McHardy T, Klair S, Boxall K, Fisher M, Cherry M, Allen CE, Addison GJ, Ellard J, Aherne GW, Westwood IM, van Montfort R, Garrett MD, Reader JC, Collins I.

Bioorg Med Chem Lett. 2010 Jul 15;20(14):4045-9. doi: 10.1016/j.bmcl.2010.05.096. Epub 2010 May 27.

PMID:
20561787
24.

Identification of inhibitors of checkpoint kinase 1 through template screening.

Matthews TP, Klair S, Burns S, Boxall K, Cherry M, Fisher M, Westwood IM, Walton MI, McHardy T, Cheung KM, Van Montfort R, Williams D, Aherne GW, Garrett MD, Reader J, Collins I.

J Med Chem. 2009 Aug 13;52(15):4810-9. doi: 10.1021/jm900314j.

PMID:
19572549
25.

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.

Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Aherne W, Rowlands M, Hayes A, Martins V, Urban F, Boxall K, Prodromou C, Pearl L, James K, Matthews TP, Cheung KM, Kalusa A, Jones K, McDonald E, Barril X, Brough PA, Cansfield JE, Dymock B, Drysdale MJ, Finch H, Howes R, Hubbard RE, Surgenor A, Webb P, Wood M, Wright L, Workman P.

Cancer Res. 2008 Apr 15;68(8):2850-60. doi: 10.1158/0008-5472.CAN-07-5256.

26.

4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.

Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews TP, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, Workman P, Wright L.

J Med Chem. 2008 Jan 24;51(2):196-218. Epub 2007 Nov 20.

PMID:
18020435
27.

Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues.

Sharp SY, Prodromou C, Boxall K, Powers MV, Holmes JL, Box G, Matthews TP, Cheung KM, Kalusa A, James K, Hayes A, Hardcastle A, Dymock B, Brough PA, Barril X, Cansfield JE, Wright L, Surgenor A, Foloppe N, Hubbard RE, Aherne W, Pearl L, Jones K, McDonald E, Raynaud F, Eccles S, Drysdale M, Workman P.

Mol Cancer Ther. 2007 Apr;6(4):1198-211.

28.

In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors.

Sharp SY, Boxall K, Rowlands M, Prodromou C, Roe SM, Maloney A, Powers M, Clarke PA, Box G, Sanderson S, Patterson L, Matthews TP, Cheung KM, Ball K, Hayes A, Raynaud F, Marais R, Pearl L, Eccles S, Aherne W, McDonald E, Workman P.

Cancer Res. 2007 Mar 1;67(5):2206-16. Erratum in: Cancer Res. 2019 Jan 1;79(1):287.

29.

Structure-activity relationships in nitrothiophenes.

Morley JO, Matthews TP.

Bioorg Med Chem. 2006 Dec 1;14(23):8099-108. Epub 2006 Aug 2.

PMID:
16887355
30.

Studies on the biological activity of some nitrothiophenes.

Morley JO, Matthews TP.

Org Biomol Chem. 2006 Jan 21;4(2):359-66. Epub 2005 Dec 15.

PMID:
16391779
31.

The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.

Cheung KM, Matthews TP, James K, Rowlands MG, Boxall KJ, Sharp SY, Maloney A, Roe SM, Prodromou C, Pearl LH, Aherne GW, McDonald E, Workman P.

Bioorg Med Chem Lett. 2005 Jul 15;15(14):3338-43.

PMID:
15955698

Supplemental Content

Loading ...
Support Center